Comparison of different chemically modified inhibitors of miR-199b in vivo

Duygu, Burcu; Juni, Rio P.; Ottaviani, Lara; Bitsch, Nicole; Wit, Jan B M; Windt, León J. De; Martins, Paula

doi:10.1016/j.bcp.2018.11.013

Cited by 24 publications

(28 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One is the use of antimiRs, common inhibitors AntigomiRs, locked nucleic acid (LNA), etc., to block the expression of miRNAs targeting mRNA in tumor and premetastatic niche [78]. MiR-15a and miR-16-1 provide indications for miRNA-based treatment, and strong regulation of clonal amplification of CLL plays a role at the level of mature leukemia [79].…”

Section: Clinical Utility Of Ncrnasmentioning

confidence: 99%

Noncoding RNAs Act as Tumor-Derived Molecular Components in Inducing Premetastatic Niche Formation

Zhang

Qiao

Zhang

et al. 2019

BioMed Research International

View full text Add to dashboard Cite

Cancer metastasis has been demonstrated as it is the culmination of a cascade of priming steps. Increasing evidence has shown that tumor-derived molecular components (TDMCs) are known as extra cellular vesicle and nonvesicle factors and serve as versatile intercellular communication vehicles which can mediate signaling in the tumor microenvironment while creating the premetastatic niche. Noncoding RNAs (ncRNAs) as one of the TDMCs have been proved in participating in the formation of the premetastatic niche. Understanding the premetastatic niche formation mechanisms through TDMCs, especially ncRNAs may open a new avenue for cancer metastasis therapeutic strategies. In this review, recent findings regarding ncRNAs function were summarized, and then the interaction with the premetastatic niche formation was studied, which highlight the potential of using ncRNAs for cancer diagnosis and therapeutic effect.

show abstract

Section: Clinical Utility Of Ncrnasmentioning

confidence: 99%

Noncoding RNAs Act as Tumor-Derived Molecular Components in Inducing Premetastatic Niche Formation

Zhang

Qiao

Zhang

et al. 2019

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…For the non-viral introduction, liposomes, nanoparticles, and hydrogels have been used to deliver non-coding RNAs for promoting vascular tissue regeneration (Li et al, 2018). Furthermore, chemical modifications of the oligonucleotide has been explored to further improve their in vivo stability and bioactivity, and include cholesterol modification, methoxyethyl modification, locked nucleic acid (LNA), and antagomirs strategies (Duygu et al, 2019).…”

Section: Non-coding Rnas For Angiogenesis In Vivomentioning

confidence: 99%

Rebuilding the Vascular Network: In vivo and in vitro Approaches

Meng

Xing

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

As the material transportation system of the human body, the vascular network carries the transportation of materials and nutrients. Currently, the construction of functional microvascular networks is an urgent requirement for the development of regenerative medicine and in vitro drug screening systems. How to construct organs with functional blood vessels is the focus and challenge of tissue engineering research. Here in this review article, we first introduced the basic characteristics of blood vessels in the body and the mechanism of angiogenesis in vivo, summarized the current methods of constructing tissue blood vessels in vitro and in vivo, and focused on comparing the functions, applications and advantages of constructing different types of vascular chips to generate blood vessels. Finally, the challenges and opportunities faced by the development of this field were discussed.

show abstract

“…While the non‐viral concept involved liposomes or nanoparticles approaches to delivery oligonucleotide to heart tissue. Besides, chemical modification, including basic cholesterol modification, 2′‐O‐(metoxyethyl) (2′MOE), 2′fluoro (2′F), locked nucleic acid and antagomirs strategy, has been widely used for in vivo lncRNA delivery 63 . Beyond lncRNA, AAV seems to be the most promising delivery strategy for continuous expression oligonucleotide in heart tissue.…”

Section: Validation Of a Lncrna‐based Gene Therapy On Non‐viral And Vmentioning

confidence: 99%